{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:30:20Z","timestamp":1791261020243,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["N42A660809"],"award-info":[{"award-number":["N42A660809"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127601","type":"journal-article","created":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T14:41:16Z","timestamp":1754836876000},"page":"127601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)"],"prefix":"10.1016","volume":"62","author":[{"given":"Viravarn","family":"Luvira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranath","family":"Lawpoolsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapong","family":"Phumratanaprapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Jongkaewwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sira","family":"Nanthapisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant","family":"Muangnoicharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supitcha","family":"Kamolratanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupa","family":"Sabmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatnapa","family":"Duangdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piengthong","family":"Narakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Surichan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Raghunandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Polyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponthip","family":"Wirachwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127601_bb0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.abm1208","article-title":"Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness","volume":"376","author":"Obermeyer","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127601_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/08830185.2022.2079642","article-title":"SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies","volume":"42","author":"Gong","year":"2023","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0015","doi-asserted-by":"crossref","first-page":"1294288","DOI":"10.3389\/fimmu.2023.1294288","article-title":"Analysis of the protective efficacy of approved COVID-19 vaccines against omicron variants and the prospects for universal vaccines","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0025","first-page":"11","article-title":"The end or a new era of development of SARS-CoV-2 virus: genetic variants responsible for severe COVID-19 and clinical efficacy of the Most commonly used vaccines in clinical practice","author":"Miteva","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127601_bb0030","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1002\/jmv.27196","article-title":"The variants question: what is the problem?","volume":"93","author":"Zella","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0035","doi-asserted-by":"crossref","first-page":"2153532","DOI":"10.1080\/21645515.2022.2153532","article-title":"Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape","volume":"19","author":"Das","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127601_bb0040","series-title":"WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127601_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.26335","article-title":"Durability of heterologous and homologous COVID-19 vaccine boosts","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2025.127601_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and Meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2025.127601_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127601_bb0060","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against omicron subvariants","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127601_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12979-021-00246-9","article-title":"Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people","volume":"18","author":"Parry","year":"2021","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2025.127601_bb0070","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127601_bb0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-022-00594-7","article-title":"Comparing hybrid and regular COVID-19 vaccine-induced immunity against the omicron epidemic","volume":"7","author":"Huang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127601_bb0080","article-title":"Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern","volume":"14","author":"McNamara","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127601_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101323","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial","volume":"45","author":"Pitisuttithum","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.127601_bb0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127601_bb0095","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127601_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127601_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0110","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO international standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127601_bb0115","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/S0140-6736(21)00982-X","article-title":"The CEPI centralised laboratory network: supporting COVID-19 vaccine development","volume":"397","author":"Kumar","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127601_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijid.2023.01.022","article-title":"Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and omicron variants","volume":"129","author":"Niyomnaitham","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127601_bb0125","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.vaccine.2023.06.043","article-title":"Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: day 28 results of a phase 1\/2 open-label trial","volume":"41","author":"Muangnoicharoen","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127601_bb0130","author":"Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2025.127601_bb0135","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127601_bb0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127601_bb0145","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127601_bb0150","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.vaccine.2022.04.078","article-title":"Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1\/2 trial in Vietnam","volume":"40","author":"Duc Dang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127601_bb0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127601_bb0160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127601_bb0165","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"issue":"904\u201311","key":"10.1016\/j.vaccine.2025.127601_bb0170","article-title":"Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans","volume":"57","author":"Tortorici","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.127601_bb0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127601_bb0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0185","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2025.127601_bb0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127601_bb0195","first-page":"8","article-title":"An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants","author":"Bates","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2025.127601_bb0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127601_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.127601_bb0210","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"issue":"5699\u2013714","key":"10.1016\/j.vaccine.2025.127601_bb0215","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127601_bb0220","first-page":"13","article-title":"The potential role of viral persistence in the post-acute sequelae of SARS-CoV-2 infection (PASC)","author":"Lupi","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.127601_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:16:29Z","timestamp":1772795789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"alternative-id":["S0264410X25008989"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127601","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127601"}}